Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 24, 2015

View Archived Issues

60 Degrees Pharmaceuticals and Singapore General Hospital to test celgosivir in dengue fever

Novel aldosterone synthase inhibitors active in monkeys

Researchers detail preclinical evaluation of altiratinib

Regenerative peptide mitigates radiation-induced gastrointestinal damage

Preclinical efficacy of a human monoclonal antibody against influenza A virus

Preclinical results presented for IKur inhibitor BMS-919373

Advaxis and MedImmune start phase I/II trial combining ADXS-HPV and durvalumab

FDA grants orphan drug designation to SER-109 for CDI in adults

AAK1 inhibitor shows potential for the treatment of neuropathic pain

Raptor Pharmaceutical to acquire inhaled fluoroquinolone therapy for cystic fibrosis

Eteplirsen granted FDA rare pediatric disease designation for DMD

Vital Therapies releases topline data from phase III trial of ELAD

TiGenix's Cx-601 achieves primary endpoint in pivotal fistula trial

Northwest Biotherapeutics confirms status of phase III trial of DCVax-L in glioblastoma multiforme

Pfizer releases topline data from phase III studies of Trumenba

Merck & Co. discloses FFAR1 agonists

Cognition Therapeutics patents sigma-2 receptor antagonists

Shijiazhuang Yiling Pharmaceutical divulges VEGFR-2 inhibitors

FDA review of Aristada ongoing

Genentech and Roche disclose anti-influenza MAbs

Peregrine and AstraZeneca collaborate to conduct bavituximab and durvalumab combination study

Lilly files for approval of ixekizumab in Japan

C4 Imaging receives NCI grant to develop MRI/CT imaging marker

Motif Bio's iclaprim shows in vitro efficacy against S. aureus

Banner MD Anderson studies olaparib for pancreatic cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...